Antibodies to Nucleocapsid Are Not Diagnostic for Long COVID.
作者信息
Brandt C T, Wiese L, Christiansen K M, Agergaard J
机构信息
Department of Infectious Diseases, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark.
Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
出版信息
Microbiol Spectr. 2023 Feb 21;11(2):e0490022. doi: 10.1128/spectrum.04900-22.
Abstract
摘要
相似文献
1
Antibodies to Nucleocapsid Are Not Diagnostic for Long COVID.核衣壳抗体对新冠后长期症状无诊断价值。
Microbiol Spectr. 2023 Feb 21;11(2):e0490022. doi: 10.1128/spectrum.04900-22.
2
Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests.SARS-CoV-2 核衣壳结合抗体的交叉反应性及其对 COVID-19 血清学检测的影响。
Viruses. 2022 Sep 14;14(9):2041. doi: 10.3390/v14092041.
3
Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.轻度 SARS-CoV-2 感染与再感染无关，并提供持久的刺突、核衣壳和病毒中和抗体。
Microbiol Spectr. 2021 Oct 31;9(2):e0008721. doi: 10.1128/Spectrum.00087-21. Epub 2021 Sep 1.
4
IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases.在许多无症状和轻症 COVID-19 病例中，针对刺突蛋白而不是核衣壳病毒蛋白产生 IgG 抗体。
Viruses. 2021 Sep 28;13(10):1945. doi: 10.3390/v13101945.
5
Obtaining a high titer of polyclonal antibodies from rats to the SARS-CoV-2 nucleocapsid protein and its N- and C-terminal domains for diagnostic test development.从 SARS-CoV-2 核衣壳蛋白及其 N 端和 C 端结构域获得针对大鼠的高滴度多克隆抗体，用于诊断检测开发。
J Immunol Methods. 2023 Nov;522:113558. doi: 10.1016/j.jim.2023.113558. Epub 2023 Sep 11.
6
Diagnostic value and characteristic analysis of serum nucleocapsid antigen in COVID-19 patients.血清核衣壳抗原在 COVID-19 患者中的诊断价值及特征分析。
PeerJ. 2023 Jun 7;11:e15515. doi: 10.7717/peerj.15515. eCollection 2023.
7
Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection.从血清中检测 SARS-CoV-2 核衣壳抗原有助于确定 COVID-19 感染时间。
J Virol Methods. 2022 Apr;302:114469. doi: 10.1016/j.jviromet.2022.114469. Epub 2022 Jan 17.
8
Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.开发一种针对 SARS-CoV-2 核衣壳的单克隆抗体。
Virology. 2021 Jun;558:28-37. doi: 10.1016/j.virol.2021.01.003. Epub 2021 Feb 1.
9
Development of a recombinant nucleocapsid protein-based ELISA for the detection of IgM and IgG antibodies to SARS-CoV-2.基于重组核衣壳蛋白的 ELISA 检测试剂盒的研制及其用于 SARS-CoV-2 特异性 IgM 和 IgG 抗体的检测
Biotechnol Appl Biochem. 2022 Dec;69(6):2592-2598. doi: 10.1002/bab.2308. Epub 2022 Jan 13.
10
Methods to evaluate the impact of SARS-CoV-2 nucleocapsid mutations on antigen detection by rapid diagnostic tests.评估 SARS-CoV-2 核衣壳突变对快速诊断检测抗原检测影响的方法。
Biotechniques. 2022 Sep;73(3):136-141. doi: 10.2144/btn-2022-0020. Epub 2022 Aug 25.
引用本文的文献
1
[S1 guidelines for the management of postviral conditions using the example of post-COVID-19].[S1 以新冠后状况为例的病毒感染后状况管理指南]
Wien Klin Wochenschr. 2023 Jul;135(Suppl 4):525-598. doi: 10.1007/s00508-023-02242-z. Epub 2023 Aug 9.
本文引用的文献
1
Self-Reported Long COVID and Its Association with the Presence of SARS-CoV-2 Antibodies in a Danish Cohort up to 12 Months after Infection.自我报告的长新冠及其与丹麦队列中感染后长达 12 个月时 SARS-CoV-2 抗体存在的关联。
Microbiol Spectr. 2022 Dec 21;10(6):e0253722. doi: 10.1128/spectrum.02537-22. Epub 2022 Nov 9.
2
Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?核蛋白血清学阳性用于检测轻度和无症状的 SARS-CoV-2 感染：COVID-19 疫苗接种后突破感染的检测补充工具？
Vaccine. 2022 Apr 1;40(15):2251-2257. doi: 10.1016/j.vaccine.2022.03.009. Epub 2022 Mar 9.
3
A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States.美国基于人群的新冠病毒抗体血清阳性寿命分析。
EClinicalMedicine. 2021 Jun;36:100902. doi: 10.1016/j.eclinm.2021.100902. Epub 2021 May 24.
Zotero 插件